Vaxart Lands $4,368,419 New Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9d5c55b1-8702-4af6-b086-0efe68aa81ea&Preview=1
Date
7/2/2012
Company Name
Vaxart
Mailing Address
20 California Street 7th Floor San Francisco, CA 94111
Company Description
The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine.
Website
http://www.vaxart.com
Transaction Type
Venture Equity
Transaction Amount
$4,368,419
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing-amended.
M&A Terms
Venture Investor
Undisclosed